Rapport Therapeutics has crossed from a proof-of-concept neuroscience story into a registrational one, and the equity now prices that transition more than it prices the cash on the balance sheet. Two parallel late-stage trials in drug-resistant focal onset seizures, branded FOCUS One and FOCUS Two, began enrolling in the June quarter after a December end-of-phase meeting with the Food and Drug Administration. The lead asset is RAP-219, a TARP gamma eight-specific AMPA-receptor negative allosteric modulator designed to quiet excitatory signaling in the hippocampus and neocortex while sparing the hindbrain circuits that produce the worst antiseizure side effects. An open-label Phase 2a study in thirty patients with implanted responsive neurostimulators produced a median clinical-seizure cut of nearly seventy eight percent and seizure freedom in roughly one patient in four. That is the evidence the market is underwriting. It is also the evidence that has not yet been tested against placebo.
The October bipolar-mania readout is the nearer binary, and it is the one the current multiple treats as an option rather than as the franchise. Management enlarged the mania trial and reworked the statistical plan so a clean result could, in principle, serve as confirmatory evidence rather than as a disposable proof-of-concept. A miss leaves the epilepsy program intact and still funded into late 2029. A hit would recast the compound as a multi-franchise molecule and force a harder look at peak-sales math that today is almost entirely an epilepsy calculation. Cash, cash equivalents, and short-term investments stood at $436 million at mid-year. The pile was down from $477 million three months earlier as late-stage start-up absorbed cash. Net loss widened to $57 million in the June quarter as research spending more than doubled. The debate is not whether Rapport can fund the next three years. The debate is whether an open-label, device-enriched seizure signal survives a conventional placebo-controlled registrational design, and whether the October mania data expand the story or merely confirm that epilepsy is the only commercially load-bearing indication.
The strongest counterargument is structural, not financial. The Phase 2a cohort was small, unblinded, and selected for patients who already carry a responsive neurostimulator, a population that is not identical to the broader drug-resistant focal-seizure market the FOCUS trials now have to enroll. Long-episode biomarker concordance was high inside that study, but concordance is not a substitute for a placebo arm. Competitive antiseizure medicines already occupy the adjunctive slot, and any late-stage miss on either efficacy or the dizziness-and-somnolence profile would collapse the probability the current enterprise value assigns to a first commercial product. Against that sits a clean capital structure, no funded debt, a Greater China license that already booked a $20 million upfront, and a cash runway that covers both FOCUS trials plus the mania readout without a forced raise. The next two prints that actually move the residual claim are the October mania topline and the first meaningful FOCUS enrollment-and-retention update.